Corvus Pharmaceuticals, Inc. CRVS
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS) is an oncology drug developer. Its lead program, soquelitinib (CPI-818, ITK inhibitor), is in Phase 3 for relapsed/refractory peripheral T cell lymphoma (PTCL). Its next catalyst on record is soquelitinib HS / asthma: Initiate Phase 1b in hidradenitis suppurativa and Phase 2 in asthma (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: soquelitinib HS / asthma — Initiate Phase 1b in hidradenitis suppurativa and Phase 2 in asthma (2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| soquelitinib | relapsed PTCL (randomized Phase 3, 150 pts) | small molecule | Phase 3 |
| soquelitinib | atopic dermatitis (Phase 2, ~200 pts, initiated March 2026) | small molecule | Phase 2 |
| soquelitinib (Angel Pharmaceuticals, Greater China) | atopic dermatitis (Phase 1b/2) | small molecule | Phase 2 |
| ciforadenant | first-line metastatic RCC with ipilimumab/nivolumab | small molecule | Phase 2 |
| mupadolimab | cancers and infectious diseases | antibody | Phase 2 |
| soquelitinib | hidradenitis suppurativa (Phase 1b planned) | small molecule | Pre-clinical |
| soquelitinib | asthma (Phase 2 planned) | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.